<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="158029">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846793</url>
  </required_header>
  <id_info>
    <org_study_id>NX02-0022</org_study_id>
    <nct_id>NCT01846793</nct_id>
  </id_info>
  <brief_title>Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)</brief_title>
  <official_title>Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nymox Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nymox Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to demonstrate the safety and efficacy of a second transrectal
      intraprostatic injection of NX-1207 given to subjects with Benign Prostatic Hyperplasia
      (BPH) who previously received an injection of NX-1207 in an earlier U.S. clinical trial of
      NX-1207.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety parameters as determined by Adverse Events, clinical laboratory test results, vital signs, physical exam and electrocardiogram (ECG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Improvement</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptomatic improvement as measured by the change in American Urological Association (AUA) Symptom Index from baseline at 90 days. The AUA Symptom Index is a standardized questionnaire that uses seven questions relating to associated BPH symptoms to provide an assessment of symptom severity on a scale from 0 (no symptoms) to 35 (most severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Volume Change</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in prostate volume from baseline to 90 days as measured by transrectal ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Peak Flow</measure>
    <time_frame>90 days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Urinary Peak Flow (Qmax) from baseline to 90 days as determined by urinary flow-rate recording (uroflowmetry).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Improvement</measure>
    <time_frame>180 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Symptomatic improvement as measured by the change in AUA Symptom Index from baseline at 180 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>BPH</condition>
  <condition>Lower Urinary Tract Symptoms (LUTS)</condition>
  <condition>LUTS</condition>
  <condition>Enlarged Prostate</condition>
  <arm_group>
    <arm_group_label>Open Label Injection of NX-1207</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraprostatic injection of 2.5 mg NX-1207</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NX-1207</intervention_name>
    <description>2.5 mg NX-1207 in 10 mL saline vehicle</description>
    <arm_group_label>Open Label Injection of NX-1207</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be male aged 45 or older.

          -  Sign an informed consent form.

          -  Be in good health.

          -  Received NX-1207 in a previous completed study (other than NX02-0020) or received
             NX-1207 or placebo in a concurrent U.S. study (NX02-0017 and NX02-0018) and completed
             their V10 (365 day) visit.

          -  Have Prostate Gland Volume ≥ 25 mL (25 g).

        Exclusion Criteria:

          -  Surgery or minimally invasive surgical therapy (MIST) for treatment of BPH after
             first NX-1207 injection

          -  Post-void residual urine volume &gt; 200 mL

          -  Presence of a symptomatic median lobe of the prostate

          -  History of use of self-catheterization for urinary retention.

          -  Urinary retention in the previous 12 months.

          -  Prostatitis

          -  Urinary tract infection more than once in the past 12 months

          -  Prostate or bladder cancer.

          -  Prostate-Specific Antigen (PSA) ≥ 10 ng/mL

          -  Poorly controlled diabetes

          -  History or evidence of illness or condition that may interfere with study or endanger
             subject

          -  Participation in a study of any investigational drug (other than NX-1207) or
             investigational device within the previous 90 days

          -  Use of specific prescribed medications that may interfere with study or endanger
             subject
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>There will be multiple sites for this clinical trial. For further information contact Nymox at</last_name>
    <phone>800-936-9669 or at</phone>
    <email>info@nymox.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Laguna Beach</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>08724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>For information concerning this clinical site, please contact Nymox at 800-936-9669.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 1, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>BPH</keyword>
  <keyword>Enlarged prostate</keyword>
  <keyword>Lower urinary tract symptoms</keyword>
  <keyword>LUTS</keyword>
  <keyword>LUTS secondary to BPH</keyword>
  <keyword>LUTS/BPH</keyword>
  <keyword>Benign prostatic obstruction (BPO)</keyword>
  <keyword>BPO</keyword>
  <keyword>Bladder outlet obstruction</keyword>
  <keyword>BOO</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
